NantHealth

NantHealth Announces FDA Marketing Authorization of Omics CoreSM: The Nation’s First Tumor-Normal Mutation Profiling of Overall Tumor Mutational Burden from Whole Exome Sequencing in Solid Tumors

Landmark FDA clearance of whole exome sequencing in vitro diagnostic (IVD) test reporting overall tumor mutation burden (TMB) by sequencing 19,396 protein-coding genes (whole exome) targeting 39 million base pairs (39 Mb) of the human genome from patient tumor and...